SCHEMBL417754

SCHEMBL417754

COCc1ccccc1SCCCC(=O)N1CCc2ccc(OC)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
RAB9A P51151 6/20 0.48
NPC1 O15118 4/20 0.48
MAPK1 P28482 2/20 0.48
TSHR P16473 3/20 0.46
BIRC2 Q13490 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 3/20 0.44
NOTUM Q6P988 2/20 0.42
TP53 P04637 2/20 0.41
GAA P10253 1/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
PKM P14618 1/20 0.41
MAOB P27338 1/20 0.41
POLB P06746 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417533 0.87 MAPT (0.50) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL413454 0.87 MAPT (0.50) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL418454 0.85 MAPT (0.48) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL10283935 0.84 MAPT (0.53) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL413397 0.83 RAB9A (0.46) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL415731 0.82 MAPT (0.52) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL418827 0.80 MAPT (0.54) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL418299 0.79 MAPT (0.42) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL416100 0.79 BIRC2 (0.50) MAPTSMN1; SMN2RAB9ANPC1MAPK1
SCHEMBL417755 0.78 BIRC2 (0.44) MAPTSMN1; SMN2RAB9ANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US claimed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 MAPT 3216/4885SMN1; SMN2 4050/4885RAB9A 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.